Naskah Publikasi Penggunaan Obat Anti Diabetes Dan Penurunan Risiko Dimensia: Scoping Review

Abstract

Background: Diabetes is still an important health problem in Indonesia. The incidence of diabetes in Indonesia increases every year. Many complications can result from diabetes, such as dementia. Diabetes has been shown to be a risk factor for the development of dementia. The risk of diabetes complications can be minimized by administering anti-diabetic drugs. This review aims to find out whether anti-diabetic drugs can help reduce the risk of dementia.

Method: Scoping review used Preferred Reporting Items for Systematic reviews and Meta-Analysis Extension for Scoping Review (PRISMA-SCR) guideline. The data sources were from PubMed, ScienceDirect, EBSCOhost, and Google scholar. The article that will be used is an article with a cohort research design with the research subjects being humans diagnosed with diabetes and the object of research being the effect of using anti-diabetic drugs on the risk of dementia.

Result: There were 38 articles that met the inclusion criteria, all of which came from developed countries, especially the United States and Taiwan. A significant reduction in the risk of dementia was reported in with administration of Metformin (the number of articles(n) = 18), Sulfonilurea (n = 12) DPP-4i (n = 8) , Insulin ( n = 1). Pioglitazone (n = 5) , Thiazolidinedion (n = 3) , SGLT-2i (n = 4) and Acarbose (n 2). However, on the other hand, an increased risk of dementia were reported with administration of Metformin (n = 4) Sulfonilurea (n = 3) , DPP-4i (n = 2) , Insulin (n = 4) and Thiazolidinedion (n = 1)

Conclusion: Cohort research from 2013-2023 shows the effect of antidiabetic drugs in reducing the risk of dementia, especially metformin, sulfonylurea and DPP-41. Research with diabetes patient subjects from developing countries needs to be carried out.